Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: HE-3235 is a synthetic adrenal hormone, an androstanediol analog, that acts as an androgen receptor antagonist. In an androgen receptor-dependent manner, it downregulates anti-apoptotic genes, while increasing the expression of pro-apoptotic genes, thus stimulating apoptosis. HE-3235 has been shown to inhibit androstenediol-dependent LNCaP cell tumor growth both in vitro (IC50 = 6 nM) and in xenograft models in vivo.
HE-3235 is supplied as a crystalline solid. A stock solution may be made by dissolving the HE-3235 in the solvent of choice. HE-3235 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of HE-3235 in these solvents is approximately 10 mg/ml. HE-3235 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, HE-3235 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. HE-3235 has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Trauger, R., Corey, E., Bell, D., et al. Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α,17β-diol (HE3235). Br. J. Cancer 100(7), 1068-1072 (2009).
Koreckij, T. D., Trauger, R. J., Montgomery, R. B., et al. HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia 11(11), 1216-1225 (2009).